Kamada (NASDAQ:KMDA) Stock Price Passes Below Two Hundred Day Moving Average of $5.45

Kamada Ltd. (NASDAQ:KMDA) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.45 and traded as low as $5.26. Kamada shares last traded at $5.31, with a volume of 57,951 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Kamada in a research report on Thursday, August 15th. Stifel Nicolaus began coverage on shares of Kamada in a research report on Wednesday, July 3rd. They set a “buy” rating and a $18.00 price target on the stock. Finally, StockNews.com lowered Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 27th.

Kamada Stock Performance

The firm has a market cap of $305.22 million, a PE ratio of 23.09 and a beta of 1.07. The stock has a 50-day simple moving average of $5.56 and a two-hundred day simple moving average of $5.45.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $42.47 million during the quarter, compared to the consensus estimate of $39.70 million. Kamada had a return on equity of 6.15% and a net margin of 9.75%. As a group, sell-side analysts anticipate that Kamada Ltd. will post 0.26 EPS for the current fiscal year.

Institutional Trading of Kamada

Several hedge funds and other institutional investors have recently bought and sold shares of KMDA. Aristides Capital LLC grew its position in shares of Kamada by 41.6% during the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after buying an additional 16,635 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Kamada by 8.2% in the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after acquiring an additional 100,800 shares in the last quarter. Finally, Y.D. More Investments Ltd raised its stake in shares of Kamada by 1,956.0% in the second quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock worth $3,643,000 after purchasing an additional 690,842 shares during the last quarter. Hedge funds and other institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.